GENERAL23 Sept 2026
Crisil revises Metropolis outlook to positive, reaffirms 'AA-' rating
Crisil has changed its outlook on Metropolis Healthcare to positive from stable, while keeping its AA- long-term and A1+ short-term ratings. For investors and lenders, this points to steadier revenue and cash flows. The company's revenue rose 24 percent to ₹1,646 crore in FY26. If you track diagnostics stocks or lend to them, treat this as reassurance, not a guarantee.
Key Statutory Highlights
- Crisil reaffirmed Metropolis Healthcare's long-term rating at AA- and its short-term bank facility rating at A1+.
- Revenue rose 24 per cent to ₹1,646 crore in FY26, and growth continued at 16.6 per cent in the first quarter of FY27.
- As on March 31, 2026, adjusted net worth stood at about ₹1,335 crore against total debt of about ₹232 crore.
Actionable Advice for Taxpayers / Founders:If you hold Metropolis shares or lend to the company, read the full Crisil note and weigh it against your own risk position. Ratings can change, so treat this as information, not a signal to buy or sell.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: